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Objectives. The purpose of this study was to determine whether 
an adverse interaction exists between radiographic contrast 
agents and thrombolytic drugs. 
Background. Coronary thrombosis may occur in the setting of 
unstable angina and after coronary angioplasty. However, the use 
of thrombolytic drugs in the setting of unstable angina has not 
been beneficial and, in one large trial of angioplasty in patients 
with unstable angina, was associated with an increased incidence 
of ischemic complications and abrupt closure. The reasons for 
these results are not clear. Coronary arteriography was performed 
in many of these trials, and it is known that fibrin structure and 
assembly are altered by radiographic contrast agents. 
Methods. Blood samples were obtained from patients before 
(n = 25) and after (n = 20) angiography using iohexol. Blood 
samples obtained before angiography were tested for response to 
streptokinase (10 and 100 IU/ml), urokinase (100, 200 and 500 
IU/ml) and recombinant issue-type plasminogen activator (rt- 
PA) (100 and 1,000 IU/ml) and the results measured. Iohexol, 
diatrizoate or ioxaglate (4% by volume) was added to separate 
aliquots of the baseline sample, and the test was repeated. Blood 
samples obtained after angiography were tested in a similar 
manner. 
Results. The onset of lysis at baseline by rt-PA at 1,000 IU/ml 
occurred at 72 -+ 8.2 s (mean -+ SD) and was markedly delayed in 
the presence of diatrizoate (527 -+ 181.7 s, p < 0.001) or iohexol 
(460 -+ 197.0 s, p < 0.001) but not ioxaglate. At 100 IU/ml, there 
was no lysis detected with rt-PA after the addition of any contrast 
agent. The addition of a contrast agent caused similar delays in 
the onset of lysis by urokinase and streptokinase; similar to rt-PA, 
the effect was smaller at higher concentrations of drug. In vivo 
blood samples obtained from the patient after angiography 
showed delays in the onset of lysis by rt-PA and urokinase but not 
streptokinase. 
Conclusions. These data demonstrate that radiographic con- 
trast agents impede fibrinolysis. This previously undescribed 
interaction was demonstrated using an in vitro test system, but 
these findings may have clinical relevance when thrombolytic 
drugs are used at the time of angiography. 
(J Am Con Cardiol 1995;25:1069-75) 
Thrombotic omplications during cardiac atheterization are 
uncommon but serious events (1,2). During coronary angio- 
plasty, the potential for coronary thrombosis is higher and 
contributes to abrupt closure. Although several reports have 
raised concerns about hrombosis pecifically related to non- 
ionic contrast agents, large studies have not confirmed this 
observation (3-6). When thrombotic complications occur dur- 
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ing cardiac catheterization, it has been noted incidentally that 
thrombolytic drugs are not particularly useful for dissolving 
clots embolized into the coronary circulation (5). One of 
several possible explanations for failure of clot lysis is that 
contrast agents alter the assembly and structure of fibrin, 
thereby making clots more resistant to the action of thrombo- 
lytic drugs. Support for this explanation comes from in vitro 
data showing that both diatrizoate and iopamidol cause the 
formation of long, thin fibrin fibrils having a lower mass/length 
ratio than normal (7). In certain disease states, fibrin assem- 
bled from thin fibrils is more resistant to fibrinolysis (8). The 
occurrence of an alteration i fibrin structure by diatrizoate or 
iohexol was confirmed in vivo using blood samples obtained 
during the course of cardiac atheterization (9). Thus, contrast 
agents as such do not impair the action of the drugs; rather, 
they cause an alteration in fibrin that renders it inherently 
more resistant to fibrinolysis. 
The alteration i fibrin caused by contrast agents could have 
importance when thrombolytic drugs are used during coronary 
interventions or when serial coronary angiography is used to 
C,1995 by the American College of Cardiology 0735-1097/95/$9.5t) 
0735-1097(94)00528-X 
1070 DEHMER ET AL. JACC Vol. 25, No. 5 
CONTRAST AGENTS AND FIBRINOLYS1S April 1995:1069-75 
evaluate thrombolytic therapy. Several trials using serial an- 
giography to evaluate the results of thrombolytic therapy in 
unstable angina have not shown a beneficial effect, and in one 
large randomized trial, it was concluded that the prophylactic 
use of urokinase before coronary angioplasty in the setting of 
unstable angina was detrimental (10-12). In the Thrombolysis 
and Angioplasty in Unstable Angina (TAUSA) trial (12), 
coronary filling defects were not decreased, and the occurrence 
of abrupt closure, ischemia and bypass surgery ranged from 
2.5 to 4 times higher in patients receiving urokinase. Because 
coronary angiography was used before drug therapy, one 
explanation for these findings might be that the radiographic 
contrast altered the structure of fibrin, which, in turn, adversely 
affected the action of urokinase. Although there is both in vivo 
and in vitro evidence for an alteration in fibrin structure by 
contrast media, to our knowledge there has not been a direct 
demonstration f an impairment in the action of thrombolytic 
drugs by contrast agents. Recently, a new method to evaluate 
the action of thrombolytic drugs has been developed and 
tested clinically (13,14). The purpose of the present study was 
to use this new method to test the hypothesis that radiographic 
contrast agents cause an impairment in the action of throm- 
bolytic drugs. 
Methods  
Patients. The study group included 25 patients randomly 
selected from those referred for diagnostic ardiac catheter- 
ization. Patients fasted for at least 8 h before collection of the 
baseline blood sample but continued to receive their regular 
medications. Also, most patients received diazepam (5 to 
10 mg) and diphenhydramine (25to 50 rag) orally 30 to 60 rain 
before the procedure. Cardiac atheterization a d angiography 
were performed from the femoral approach using standard 
techniques. The study was approved by the Human Studies 
Committee of the institution, and all subjects gave written 
informed consent for the procedure. 
Sample collection and preparation. After vascular access 
was obtained, a baseline 10-ml blood sample was collected 
from the femoral vein or artery before heparin or radiographic 
contrast administration. The blood was placed in a collection 
tube (Vacutainer no. 367705, Becton Dickinson), where 4.5 ml 
of blood mixed with 0.5 ml of buffered sodium citrate. Samples 
were kept at room temperature until testing, which was 
completed within 6 h. This sample was tested to establish the 
baseline responses to the fibrinolytic drugs. 
Radiographic ontrast medium was then added to an 
aliquot of the baseline blood sample, and it was tested again. 
The amount of radiographic ontrast medium within the 
vasculature during and after angiography is constantly chang- 
ing as contrast agent is injected and simultaneously excreted. 
When contrast agent is injected into a coronary artery, the 
concentration is very high within the artery for -5  to 10 s. 
However, this rapidly decreases after each injection to some 
ambient level that slowly increases during the procedure and 
then decreases. We modeled this low level of circulating 
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Figure 1. Signal amplitude of the paramagnetic particle oscillation 
plotted against time to determine lysis onset ime. Signal amplitude 
reflects the motion of the paramagnetic particles in response to the 
oscillating magnetic field. As thrombin-stimulated clot formation 
occurs, oscillation of the paramagnetic particles i restricted, and the 
plotted lines converge. When the drug causes clot lysis, the paramag- 
netic particles are released from the confines of the polymerizing fibrin 
network, oscillation amplitude increases, and the plotted lines diverge. 
Lysis onset ime is defined as the time in seconds from application of
the blood drop into the sample well to the time that signal amplitude 
begins to increase during clot lysis. 
contrast medium by mixing 40/xl of contrast agent with 960/4 
of blood to yield a mixture that was 4% contrast medium by 
volume. This was based on an estimated contrast medium 
administration of 200 ml/procedure and a blood volume of 
5 liters. Separate valuations were performed using the ionic 
contrast agent diatrizoate (Hypaque-76, Sanofi-Winthrop), the 
nonionic agent iohexol (Omnipaque, Sanofi-Winthrop) and 
ioxaglate (Hexabrix, Mallinckrodt), an ionic, low osmolar 
contrast agent. To confirm the effects of contrast, a second 
blood sample was obtained at the conclusion of the procedure 
in 20 of the patients. All had received iohexol (155 + 36 ml) for 
their angiography. This in vivo sample was tested without 
added contrast medium using identical procedures. 
Test procedures. The assessment of fibrinolysis was per- 
formed using the dry reagent method escribed by Oberhardt 
et al. (13). The test system consists of a microprocessor-based 
analyzer and individual disposable test cards that contain a 
known concentration f a drug. For each analysis, a new test 
card is placed in the analyzer and warmed to 37°C. An 
unmeasured drop of whole blood is placed in the sample well 
of the card and drawn into the reaction chamber by capillary 
action, this starts the timing sequence. In the reaction cham- 
ber, blood mixes with buffers and thrombin, which initiates clot 
formation. The reaction chamber also contains inert paramag- 
netic particles of iron oxide <1 ~m in diameter. As the 
paramagnetic particles are freed from the dry reagent matrix, 
they are driven into oscillation by orthogonal magnetic fields, 
one of which is varied with time. The oscillation of the particles 
is monitored optically during clot formation and lysis and 
displayed graphically by the computer (Fig. 1). Optical detec- 
tion of particle motion is performed in the infi-ared range 
(900 nm) and thus is unaffected by hemoglobin concentration. 
Lysis onset time is defined as the time, in seconds, from 
dissolution of the dry reagents to the onset of an increase in 
signal amplitude during clot lysis and was the variable moni- 
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tored as the test end point. Lysis onset time was determined 
automatically b the computer using a mathematical algorithm 
to detect he increase in signal amplitude at the onset of lysis. 
Separate test cards were used to test streptokinase (Astra, Inc.) 
at concentrations of 10 and 100 IU/ml, recombinant tissue-type 
plasminogen activator (rt-PA) (Genentech, Inc.) at concentra- 
tions of 100 and 1,000 IU/ml and urokinase (Abbott Labora- 
tories) at concentrations of 100, 200 and 500 IU/ml. 
Statistical analyses. Comparison of lysis onset times at 
baseline and with the contrast agents added was accomplished 
with a repeated-measures analysis of variance followed by a 
Neuman-Keuls test when a significant difference was detected 
among the variables (15). Comparison of the baseline and in 
vivo contrast samples was performed with a paired t test. All 
values are displayed as mean value ± SD, and p -< 0.05 was 
considered significant. 
Resu l ts  
Study patients. There were 15 men and 10 women in the 
study group (mean age 64 _+ 12 years). The diagnosis derived 
from the procedure was coronary artery disease in 20 and an 
infiltrative cardiomyopathy in 1; no definite pathologic abnor- 
malities were found in four patients. None of the patients had 
previously received a thrombolytic drug. Other baseline char- 
acteristics of the study group are shown in Table l. 
In vitro test results. The baseline lysis onset time with 
streptokinase at 10 IU/ml was 97 ± 14.7 s. Diatrizoate and 
iohexol both prolonged lysis onset time to 144 ± 43.4 and 
135 _ 61.1 s, respectively (p < 0.001). However, lysis onset 
time was not prolonged by ioxaglate (106 ± 20.8 s). A similar 
pattern was seen when streptokinase was tested at 100 IU/ml. 
As expected, the baseline lysis onset time was shorter (45 ± 
6.9 s) at the higher concentration of streptokinase. With the 
addition of diatrizoate, lysis onset ime increased to 64 _+ 19.6 s 
(p < 0.001), and with iobexol it increased to 51 ± 9.3 s (p < 
0.05), but with the addition of ioxaglate it was not increased 
(49 + 7.5 s) compared with the baseline. These findings are 
summarized in Figure 2. 
When rt-PA was tested at a concentration f 100 IU/ml, the 
baseline lysis onset time was 552 ± 114.1 s. When repeat 
testing was performed after the addition of any of the contrast 
agents, no lysis occurred up to 1,000 s, at which point the test 
was automatically terminated by the computer software (Fig. 
Table 1. Clinical Characteristics of 25 Study Patients 
Age (yr) 
Gender 
Men 
Women 
Race 
Black 
Whitc 
Smoker 
Diabetes mellitus 
Hypertension 
Medications 
Aspirin 
Angiotensin-converting enzyme inhibitor 
Calcium channel blockers 
Diuretic drugs 
Nitrates 
Digoxin 
Beta-blockers 
63 +- 12 
15 (60%) 
lo (40%) 
8 (32%) 
17 (68%) 
5 (20%) 
9 (36%) 
16 (64%) 
16 (64%) 
3 (12%) 
11 (44%) 
8 (32%) 
12 (48%) 
4 (16%) 
5 (20%) 
Data presented are mean value +_ SD or number (%) of patients. 
3). At a concentration f 1,000 IU/ml of rt-PA, the baseline 
lysis onset ime was 72 + 8.2 s. With the addition of diatrizoate, 
lysis onset time increased over sixfold to 527 +_ 181.7 s (p < 
0.001), and with iohexol it increased to 460 + 197.0 s (p < 
0.001). However, with the addition of ioxaglate, there was no 
significant alteration of lysis onset ime (118 _+ 14.9 s). 
At the lowest dose of urokinase tested (100 IU/ml), the 
baseline lysis onset ime was 201 _+ 64.4 s. Compared with the 
baseline value, the lysis onset ime was significantly prolonged 
by diatrizoate (365 _+ 151.0 s, p < 0.001), iohexol (341 + 
151.8 s, p < 0.001) and ioxaglate (323 + 97.3 s, p < 0.001), with 
the prolongation by diatrizoate significantly greater than that 
by the other two contrast agents (Fig. 4). The baseline lysis 
onset ime at 200 IU/ml of urokinase was 113 + 26.7 s, and the 
addition of each contrast agent caused it to prolong signifi- 
cantly. Again, diatrizoate caused more prolongation than 
iohexol or ioxaglate. At the highest dose of urokinase tested, 
diatrizoate continued to prolong lysis onset time (134 _+ 
155.2 s). However, lysis onset ime was not significantly altered 
by the addition of iohexol (96 _+ 34.1 s) or ioxaglate (104 + 
96.4 s). As reflected by the larger standard eviations for all of 
the testing performed with urokinase, there was considerably 
more variability in the individual responses after the addition 
of the various contrast agents. 
2OO 
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Figure 3. Lysis onset imes with recom- 
binant tissue-type plasminogen activa- 
tor (rt-PA) before and after contrast 
agent administration. Lysis onset imes 
in seconds are shown at baseline and 
after the addition of diatrizoate, io- 
hexol or ioxaglate at 4% by volume 
(n = 25). Results for 100 IU/ml (left) 
and 1,000 IU/ml (right) of rt-PA are 
shown. *p < 0.001 versus baseline 
value. Error bars = 1 SD. 
In vivo test results. No alteration in fibrinolysis by strep- 
tokinase at either concentration could be measured in the 
samples obtained after angiography with iohexol (Table 2). 
However, fibrinolysis by both rt-PA and urokinase was affected 
significantly. At 100 IU/ml of rt-PA, mean lysis onset time was 
increased by 37%, and at 1,000 IU/ml it increased by 18%. 
With urokinase, the mean lysis onset times increased 15%, 
10% and 7% at 100, 200 and 500 IU/ml, respectively. 
Discuss ion  
The hemodynamic and electrophysiologic effects of contrast 
agents have been well characterized, but less is known about 
their effects on blood and coagulation. Many studies (16) have 
shown that contrast agents are weak anticoagulant agents, with 
ionic agents having a more potent effect han nonionic agents. 
In addition, both in vitro and in vivo studies (7,9) have shown 
that fibrin assembly in the presence of contrast agents is 
altered with the formation of thin fibrils having a low mass/ 
length ratio compared with normal. Fibrin fibrils of a similar 
structure occur naturally in certain disease states, and blood 
clots formed in such cases are known to be resistant o the 
action of thrombolytic drugs (8). We therefore hypothesized 
that the action of fibrinolytic drugs would be impaired when 
tested on fibrin assembled in the presence of contrast agents. 
The results of the present study confirm this hypothesis. Our in 
vitro data show that diatrizoate and iohexol delayed the onset 
Figure 4. Lysis onset times with urokinase before and after contrast 
agent administration. Lysis onset times in seconds are shown at 
baseline and after addition of diatrizoate, iohexol or ioxaglate at 4% by 
volume (n = 25). Results for 100 IU/ml (left), 200 IU/ml (middle) 500 
IU/ml (right) of urokinase are shown. *p < 0.001, +p < 0.005, *p < 
0.025 versus baseline value. Error bars = 1 SD. 
of lysis induced by all drugs tested. Ioxaglate delayed the onset 
of lysis by rt-PA and urokinase but not by streptokinase. With 
all of the drugs tested, increasing the concentration reduced 
the prolongation of onset of lysis induced by the contrast 
agents. To confirm that this was not simply an in vitro ob- 
servation, a second blood sample was obtained from a subset of 
the study patients at the conclusion of angiography. This 
showed that iohexol delayed the onset of lysis by rt-PA and 
urokinase but not by streptokinase. 
Drug concentrations tested. Because the impairment in 
fibrinolysis related to the contrast media was reduced by 
increasing concentrations of drug, it is important to relate the 
concentrations of drug that we tested to existing data about 
drug concentrations during therapy. Several studies have ex- 
amined the concentrations of rt-PA during clinical use of the 
drug. Steady-state rt-PA concentrations were measured 60 rain 
after the start of an infusion at 0.75 mg/kg body weight. At 
this dose, the mean plasma rt-PA level was 1.2 _+ 0.6/.tg/ml 
(696 IU/ml), and the euglobulin fibrinolytic activity was 910 _+ 
735 IU/ml (17). In another study (18), plasma levels of rt-PA 
measured 50 min after beginning a more conventional dosing 
schedule were 1,668 _+ 966 ng/ml (967 IU/ml). Similar levels of 
rt-PA have been documented in other studies (19-22). Be- 
cause we used whole blood instead of plasma for our measure- 
ments, the concentration of rt-PA that we tested should be 
clinically relevant. Unfortunately, similar information on in 
vivo concentrations of streptokinase after human administra- 
tion are very limited (23,24). However, if a typical dose of 1.5 
million IU of streptokinase were given as a bolus with a blood 
volume of 5 liters, the resulting concentration could be in the 
range of 300 IU/ml. Because the actual rate of administration 
is slower, and there will be some simultaneous elimination of 
the drug, the concentrations of streptokinase t sted seem a 
600- 
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Table 2. Mean (_+SD) Lysis Onset Times (in seconds) at Baseline 
and After Angiography With Iohexol in 20 Patients 
Baseline (before After Contrast 
contrast agent) Agent 
Streptokinase 
10 IU/ml 97 + 16.0 101 _+ 14.4 
100 IU/ml 44 _- 5.2 43 _+ 3.7 
rt-PA 
100 IU/ml 541 + 118.9 714 _+ 168.4' 
1,000 IU/ml 71 + 7.3 84 -- 27.7? 
Urokinase 
100 IU/ml 185 _+ 30.3 213 ~_ 44.7* 
200 IU/ml 106 + 14.0 117 z 23.3* 
500 IU/ml 61 + 8.9 65 -- 10.1-~ 
*p < 0.001. +p < 0.04. :~p < 0.02. rt-PA = recombinant tissue-type 
plasminogen activator. 
reasonable approximation of the clinical concentrations. To 
our knowledge, there are no clinical data on concentrations of 
urokinase during therapy, and these would be more difficult o 
estimate because the drug is often infused slowly directly into 
a coronary artery or occluded aortocoronary bypass graft 
(25,26). 
Concentration of contrast media. The impairment in fi- 
brinolysis demonstrated in this study occurred at low concen- 
trations of contrast media. We tested aconcentration f 4% by 
volume as an approximation ofthat circulating during a typical 
procedure. During the injection of contrast agent into a 
coronary artery, the local concentration is transiently very high, 
but between i jections the arterial surface is exposed to a much 
lower concentration for a longer period of time. Although it 
was not measured irectly, the amount of contrast in the in 
vivo blood samples obtained at the end of the procedure was 
most likely much lower than the 4% by volume used for the in 
vitro testing. In these samples, an impairment in thrombolysis 
by rt-PA and urokinase still was demonstrated, but of a smaller 
magnitude. Obviously, the most relevant concentration f dye 
to measure would be that occurring locally immediately adja- 
cent to a forming thrombus, but this would be difficult to 
determine in a clinical study. Although the concentration f 
contrast agent is continuously changing during a procedure, 
the amounts that we used could occur clinically for more than 
a brief period of time. 
Relevance to clinical situations. The implication of our 
results is that thrombus developing in the presence of circu- 
lating contrast agents is more resistant to thrombolysis. There 
are three clinical situations inwhich the possibility of coronary 
thrombus is greatest. First, in unstable angina, numerous 
studies have defined the pathophysiologic sequence l ading to 
partial or complete thrombotic occlusion of a coronary artery 
(27). It is known that the surface of a fragmented or fresh 
thrombus is very active and a potent stimulus for further 
thrombus formation (28). Second, with coronary interventions 
there is a strong stimulus to thrombosis created by the 
mechanical trauma of the procedure. Finally, acute myocardial 
infarction is frequently the consequence of coronary thrombo- 
sis. In these clinical situations, performing angiography would 
expose xisting or developing thrombus to contrast agent, and 
the characteristics of fibrin forming could be altered. It would 
be difficult to directly test the hypothesis that contrast agent 
administration impairs thrombolysis n a prospective clinical 
trial, but some insight can be gained by reviewing studies of 
thrombolytic therapy for unstable angina (29-36). 
A recent recta-analysis by Moliterno et al. (37) on pooled 
data from 12 studies involving 2,368 patients with unstable 
angina showed no effect of thrombolytic therapy on the 
occurrence of major clinical events (death and myocardial 
infarction). In some of these trials, angiography was performed 
immediately before the administration of the thrombolytic 
drug and thus may have affected the results. However, in 
several of the smaller trials, angiography was not performed 
until after thrombolytic therapy, and a decrease in clinical 
ischemic events was found. However, other factors are likely to 
be involved, because the large Thrombolysis in Myocardial 
Infarction (TIMI)-IIIB (38) study did not show a favorable 
effect of thrombolytic drugs in unstable angina, and the 
patients did not receive radiographic contrast before thrombo- 
lytic drug was given. 
Additional clinical data potentially supporting an adverse 
interaction between contrast agents and thrombolytic drugs 
come from the TAUSA trial (11,12). In that study, 469 patients 
with unstable angina were randomized toreceive intracoronary 
urokinase or placebo after baseline angiography but before 
angioplasty of the culprit lesion. Those receiving urokinase had 
a significantly higher incidence of abrupt vessel closure and 
isehemic omplications compared with the placebo group. The 
TAUSA investigators eported a higher incidence of angio- 
graphic dissections in their cohort and speculated that the 
increased ischemic omplications in the urokinase group could 
be related to greater wall hemorrhage in the presence of 
urokinase. Our observations suggest an additional potential 
mechanism related to the impairment of fibrinolysis by con- 
trast agents. 
Study limitations. The test method we used to quantify the 
thrombolytic action of a drug has been shown to be reproduc- 
ible with a low coefficient of variation for replicate measure- 
ments (13,14). However, there are some potential limitations. 
1) Although this test quantifies the thrombolytic potential of a 
particular drug, the actual effectiveness in vivo may differ. 
Clots formed in the test system may differ from those formed 
in vivo. Arterial thrombi are often platelet rich, whereas clots 
formed in vitro tend to be platelet poor and thus may behave 
differently during lysis. Discrepancies between the behavior of 
a thrombolytic drug in vitro and in vivo and the effectiveness in 
clots of differing composition have been demonstrated in 
animal models (39,40). 2) In vitro testing with known concen- 
trations of a thrombolytic drug may not correspond irectly 
with the actual in vivo concentration achieved. Collen et al. 
(41) showed that after a standard ose of rt-PA, there was 
considerable variation in the plasma rt-PA level among pa- 
tients. 3) Because it would be very difficult to measure the 
actual concentration f contrast within the coronary artery, it 
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was estimated, as was the duration of exposure. Although these 
estimations seem reasonable, their relation to actual clinical 
situations is unknown. 4) Blood samples were obtained from 
either an artery or a vein, and thus there could be some small 
variability in the results related to the source of the blood 
sample. 5) The exact relation between a delay in the onset of 
lysis, as measured here, and the clinical effectiveness ofa drug 
is unknown. However, despite these limitations, when our 
observations are considered within the context of the available 
clinical data, they suggest hat an important interaction exists 
between contrast agents and the action of fibrinolytic drugs. Of 
the drugs tested, streptokinase seemed to be slightly less 
affected by contrast agent han the other drugs, and ioxaglate 
appeared to cause the least interference in fibrinolysis. 
Conclusions. Recently, there has been debate supported 
by in vivo and in vitro data suggesting that procedures using 
certain radiographic contrast media may facilitate thrombotic 
processes in vitro (42-46). Little attention has been given to 
the possible ffects of contrast agents on fibrinolysis. This study 
demonstrates that contrast agents can alter the response of 
lytic drugs. Although demonstrated in an in vitro test system, 
these results may have considerable clinical relevance, and the 
possibility of this type of interaction has not been previously 
identified. 
We thank the technical staff of the C. V. Richardson Cardiac Catheterization 
Laboratory, University of North Carolina Hospitals, for their support in the 
performance of this study. 
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